By downregulating the PI3K/AKT pathway, a central node in HCC progression, cinnamic acid could potentially overcome or delay resistance mechanisms in patients who receive standard targeted agents or immunotherapies [33]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.